Creo Medical Group PLC (AIM:CREO, FRA:1RC) (AIM:CREO, FRA:1RC) Craig Gulliford joins Proactive London's Katie Pilbeam to talk about the genesis of the company, their strategic growth plans and the first six months of 2021.
The medical device company managed to secure the first sales of its revolutionary Speedboat Inject endoscopic device in the US and Europe.The product combines the benefits of bipolar radiofrequency and super high-frequency microwave energy to allow precise cutting in the upper and lower gastrointestinal tract when removing obstructions such as polyps.
Turning to the financials, the company booked total sales of £12.9mln for the period but made an underlying loss of £7.7mln, reflecting the investment made developing and commercialising its products.